首页> 外文期刊>Journal of Pharmacological and Toxicological Methods >Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
【24h】

Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.

机译:逐搏QT间期变异性,但QT延长本身无统计学意义,预示了麻醉的甲氧胺致敏兔子的药物诱发的扭转性扭转性发作。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: Accumulating evidence suggest that drug-induced QT prolongation per se poorly predicts repolarisation-related proarrhythmia liability. We examined whether beat-by-beat variability of the QT interval may be a complementary proarrhythmia marker to QT prolongation. METHODS: Anaesthetised rabbits sensitized towards developing torsades de pointes (TdP) were infused for 30 min maximum with explorative antiarrhythmic compounds characterised as mixed ion channel blockers. Based on the outcome in this model the compounds were classified as having a low (TdPlow; n=5), intermediate (TdPintermediate; n=7) or high (TdPhigh; n=10) proarrhythmic potential. Dofetilide (n=4) was included as a representative of a selective IKr-blocking antiarrhythmic with known high proarrhythmic potential. QT interval prolongation and beat-by-beat QT variability (quantified as the short-term variability, STV) were continuously assessed during the infusion or up to the point where ventricular proarrhythmias were induced. RESULTS: All compounds significantly prolonged the QT interval. For TdPlow and TdPhigh compounds the QT interval maximally increased from 169 +/- 14 to 225 +/- 28 ms (p<0.05) and from 186 +/- 21 to 268 +/- 42 ms (p<0.01), respectively. Likewise, in the dofetilide-infused rabbits the QT interval maximally increased from 177 +/- 11 to 243 +/- 25 ms (p<0.01). In contrast, whereas the STV in rabbits administered the TdPhigh compounds or dofetilide significantly increased prior to proarrhythmia induction (from 1.6 +/- 0.4 to 10.5 +/- 5.6 ms and from 1.6 +/- 0.5 to 5.9 +/- 1.8 ms, p<0.01) it remained unaltered in the TdPlow group (1.3 +/- 0.6 to 2.2 +/- 0.9 ms). In the TdPintermediate group, rabbits experiencing TdP had a similar maximal QT prolongation as the non-susceptible rabbits whereas the change in the STV was significantly different (from 0.9 +/- 0.5 to 8.7 +/- 7.3 ms vs 0.8 +/- 0.3 to 2.5 +/- 1.1 ms). DISCUSSION: It is concluded from the present series of experiments in a sensitive rabbit model of TdP that increased beat-by-beat QT interval variability precedes drug-induced TdP. In addition, assessment of this potential proarrhythmia marker may be useful in discriminating highly proarrhythmic compounds from compounds with a low proarrhythmic potential.
机译:简介:越来越多的证据表明,药物诱导的QT延长本身很难预测与复极相关的心律失常的发生率。我们检查了QT间期的逐次变异是否可能是QT延长的补充性心律失常标志。方法:将麻醉的兔子对发展中的尖端扭转型室速(TdP)致敏,并以探索性抗心律不齐化合物为特征,以混合离子通道阻滞剂为特征,最长注入30分钟。基于该模型中的结果,将化合物分类为具有低心律失常潜力(TdPlow; n = 5),中等(TdPintermediate; n = 7)或高(TdPhigh; n = 10)。多芬利特(n = 4)被包括作为具有已知高心律失常潜力的选择性IKr阻滞抗心律失常的代表。在输注期间或直至诱发室性心律失常的时刻,连续评估QT间隔延长和逐搏QT变异性(量化为短期变异性,STV)。结果:所有化合物均显着延长了QT间隔。对于TdPlow和TdPhigh化合物,QT间隔分别从169 +/- 14 ms最大增加到225 +/- 28 ms(p <0.05)和从186 +/- 21 ms最大增加到268 +/- 42 ms(p <0.01)。同样,在注入多芬利特的兔子中,QT间隔从177 +/- 11毫秒最大增加到243 +/- 25毫秒(p <0.01)。相反,在诱发心律不齐之前,给予TdPhigh化合物或多美替利的兔子的STV明显增加(从1.6 +/- 0.4到10.5 +/- 5.6 ms和从1.6 +/- 0.5到5.9 +/- 1.8 ms,p <0.01),在TdPlow组中保持不变(1.3 +/- 0.6至2.2 +/- 0.9 ms)。在TdP中间体组中,经历TdP的兔子的最大QT延长与不敏感的兔子相似,而STV的变化则显着不同(从0.9 +/- 0.5到8.7 +/- 7.3 ms与0.8 +/- 0.3 2.5 +/- 1.1毫秒)。讨论:从目前的一系列实验中得出的结论是,在敏感的TdP兔模型中,逐次QT间隔变异性增加是在药物诱导的TdP之前。另外,评估这种潜在的心律失常标志物可能有助于区分高度心律失常的化合物与具有低心律失常潜力的化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号